The REDUCE LAP-HF II study identified heart failure patients who may benefit from receiving a new transcatheter implant manufactured by Corvia Medical.

The study's authors focused on data from the previously completed EMPEROR-Reduced and EMPERIOR-Preserved trials.

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C. 

Sulfonylureas, researchers wrote, "may best be avoided" among patients with both HF and diabetes. 

As one might expect, the largest economic burden linked to HF is related to hospitalizations.

The use of these devices when treating certain high-risk patients is still recommended.  

Cardiologists and oncologists should collaborate to guide the optimal management of patients with HF and cancer.